[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO976112D0 - 1,6-disubstituted isochromes for the treatment of migraine - Google Patents

1,6-disubstituted isochromes for the treatment of migraine

Info

Publication number
NO976112D0
NO976112D0 NO976112A NO976112A NO976112D0 NO 976112 D0 NO976112 D0 NO 976112D0 NO 976112 A NO976112 A NO 976112A NO 976112 A NO976112 A NO 976112A NO 976112 D0 NO976112 D0 NO 976112D0
Authority
NO
Norway
Prior art keywords
isochromes
migraine
disubstituted
treatment
disubstituted isochromes
Prior art date
Application number
NO976112A
Other languages
Norwegian (no)
Other versions
NO976112L (en
Inventor
Michael D Ennis
Ruth E Tenbrink
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of NO976112D0 publication Critical patent/NO976112D0/en
Publication of NO976112L publication Critical patent/NO976112L/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/76Benzo[c]pyrans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO976112A 1995-06-30 1997-12-29 1,6-disubstituted isochromes for the treatment of migraine NO976112L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74195P 1995-06-30 1995-06-30
US1123496P 1996-02-06 1996-02-06
PCT/US1996/008681 WO1997002259A1 (en) 1995-06-30 1996-06-07 1,6-disubstituted isochromans for treatment of migraine headaches

Publications (2)

Publication Number Publication Date
NO976112D0 true NO976112D0 (en) 1997-12-29
NO976112L NO976112L (en) 1998-03-02

Family

ID=26668092

Family Applications (1)

Application Number Title Priority Date Filing Date
NO976112A NO976112L (en) 1995-06-30 1997-12-29 1,6-disubstituted isochromes for the treatment of migraine

Country Status (12)

Country Link
EP (1) EP0836599A1 (en)
JP (1) JPH11509532A (en)
AU (1) AU6252296A (en)
BR (1) BR9609631A (en)
CA (1) CA2225282A1 (en)
CZ (1) CZ418597A3 (en)
FI (1) FI974640A0 (en)
MX (1) MX9710260A (en)
NO (1) NO976112L (en)
PL (1) PL324319A1 (en)
SK (1) SK164297A3 (en)
WO (1) WO1997002259A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2370270A (en) * 2000-12-20 2002-06-26 Lilly Co Eli Pharmaceutical compounds
US7335660B2 (en) 2001-12-19 2008-02-26 Eli Lilly And Company Isochroman compounds for treatment of CNS disorders
GB0130339D0 (en) * 2001-12-19 2002-02-06 Lilly Co Eli Isochroman compounds
US7110576B2 (en) 2002-12-30 2006-09-19 Pitney Bowes Inc. System and method for authenticating a mailpiece sender
EP1748995B1 (en) 2004-05-05 2010-02-24 F. Hoffmann-La Roche AG Arylsulfonyl benzodioxanes useful for modulation the 5-ht6 receptor, the 5-ht2areceptor or both
EP1831191B1 (en) 2004-12-21 2008-05-21 F. Hoffmann-La Roche AG Chroman derivatives and their use as 5-ht receptor ligands
KR100965190B1 (en) 2004-12-21 2010-06-24 에프. 호프만-라 로슈 아게 Chroman derivatives and uses thereof in the treatment of cns disorders
AU2005318595B2 (en) 2004-12-21 2011-03-03 F. Hoffmann-La Roche Ag Tetralin and indane derivatives and uses thereof
RU2396255C2 (en) 2004-12-21 2010-08-10 Ф. Хоффманн-Ля Рош Аг Tetraline and indan derivatives and application thereof
JP2008524277A (en) 2004-12-21 2008-07-10 エフ.ホフマン−ラ ロシュ アーゲー Tetralin and indane derivatives and their use as 5-HT antagonists
NZ567285A (en) 2005-11-03 2010-06-25 Hoffmann La Roche Arylsulfonylchromans as 5-HT6 inhibitors indolylmaleimide derivatives as protein kinase inhibitors
BRPI0713742A2 (en) 2006-06-20 2013-02-13 Hoffmann La Roche arylsulfonyl naphthalene derivatives and uses of these
MX2008015843A (en) 2006-06-20 2009-01-09 Hoffmann La Roche Tetralin and indane derivatives and uses thereof.
EP2076489A1 (en) 2006-06-20 2009-07-08 F. Hoffmann-Roche AG Arylsulfonamidyl tetralin derivatives and uses thereof
EP2404897A4 (en) * 2009-03-05 2014-02-26 Sumitomo Chemical Co Method for producing halogen-substituted benzene dimethanol

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1552004A (en) * 1976-05-26 1979-09-05 Takeda Chemical Industries Ltd Isochroman derivatives
US5877317A (en) * 1993-12-28 1999-03-02 Pharmacia & Upjohn Company Heterocyclic compounds for the treatment of CNS and cardiovascular disorders

Also Published As

Publication number Publication date
BR9609631A (en) 1999-03-02
JPH11509532A (en) 1999-08-24
NO976112L (en) 1998-03-02
WO1997002259A1 (en) 1997-01-23
MX9710260A (en) 1998-03-29
EP0836599A1 (en) 1998-04-22
CA2225282A1 (en) 1997-01-23
FI974640A (en) 1997-12-30
SK164297A3 (en) 1998-09-09
CZ418597A3 (en) 1998-06-17
AU6252296A (en) 1997-02-05
PL324319A1 (en) 1998-05-25
FI974640A0 (en) 1997-12-30

Similar Documents

Publication Publication Date Title
NO981800D0 (en) Process for the preparation of 1,1,1,3,3-pentafluoropentane
NO961483L (en) Process for the treatment of oily formation
ZA961150B (en) Substituted isoxazoles for the treatment of inflammation.
NO976112D0 (en) 1,6-disubstituted isochromes for the treatment of migraine
IL135648A0 (en) Novel 3, 6-hemiketals from the class of 9a-azalides
IT1292552B1 (en) DEVICE FOR THE APPLICATION OF COATINGS.
HK1017684A1 (en) Novel substituted 4-(1h-benzimidazol-2-yl)(1,4)diazepanes useful for the treatment of allergic diseases
FI973173A0 (en) Process for the treatment of condensate
FI973644A (en) New process for the preparation of 2,3-dihydrobenzofuranol derivatives
DK0815092T3 (en) Process for the preparation of 1,2-benzisothiazolin-3-ones
NO985535L (en) Process for the preparation of 1,3-alkanediols
NO973366D0 (en) Procedure for the treatment of multiple sclerosis
NO960307D0 (en) Process for the preparation of substituted 4,6-diamino-5-cyanopyrimidines
IL113057A0 (en) Compositions for the treatment of dandruff
NO179101C (en) Process for the preparation of diblocked 2,3-hydroxymethylcyclobutanol
FI964829A (en) Process for the preparation of 2,2,4-trimethyl-1,3-pentanediolisobutyrate
HK1010095A1 (en) Use of 8,9-dehydroestrone for the manufacture of amedicament for the treatment of diseases caused byfree radicals.
EP0579077A3 (en) 1,3,4-thiadiazinones for the treatment of cardiovascular diseases
DK0783491T3 (en) Process for the preparation of 3,3,5-trichloro-glutarimide
NO962812D0 (en) Procedure for the treatment of pneumonia
FI954263A0 (en) For the purposes of this Regulation, the application was made
FI951660A0 (en) For the purposes of this Regulation
FI954795A0 (en) For the purposes of this Regulation
RU95117268A (en) MEANS FOR TREATMENT OF ATOPIC DERMATITIS
FI940088A0 (en) Regulation / Regulation For the purposes of this Regulation, the provisions of this Regulation shall apply